• QbD Group requalifies as Best Managed Company

    Friday May 13th 2022

  • Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions

    Thursday May 12th 2022

  • Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

    Thursday May 12th 2022

  • Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

    Tuesday May 10th 2022

  • UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Tuesday May 10th 2022

  • Quality by Design (QbD) becomes QbD Group, consolidating its offerings to support the development of innovative life science products, “from idea to patient”

    Monday May 9th 2022

  • Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)

    Monday May 9th 2022

  • Ziphius Vaccines and Ghent University publish promising data from self-amplifying RNA platform in Molecular Therapy

    Friday May 6th 2022

  • Your news here?

  • argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia

    Thursday May 5th 2022

  • The European Spatial Biology Center (ESBC): State-of-the-art spatial biology services enabled at scale in Leuven

    Thursday May 5th 2022

  • New study led by Memorial Sloan Kettering Cancer Center (NY, US) shows Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods

    Wednesday May 4th 2022


Strategic Partners